Xatmep is a Oral Solution in the Human Prescription Drug category. It is labeled and distributed by Silvergate Pharmaceuticals, Inc.. The primary component is Methotrexate.
Product ID | 52652-2001_0587efc3-e149-4fd0-b597-9a8a5212e077 |
NDC | 52652-2001 |
Product Type | Human Prescription Drug |
Proprietary Name | Xatmep |
Generic Name | Methotrexate |
Dosage Form | Solution |
Route of Administration | ORAL |
Marketing Start Date | 2017-05-01 |
Marketing Category | NDA / NDA |
Application Number | NDA208400 |
Labeler Name | Silvergate Pharmaceuticals, Inc. |
Substance Name | METHOTREXATE |
Active Ingredient Strength | 3 mg/mL |
Pharm Classes | Folate Analog Metabolic Inhibitor [EPC],Folic Acid Metabolism Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2017-05-01 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA208400 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2018-08-13 |
Marketing Category | NDA |
Application Number | NDA208400 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2017-05-01 |
Ingredient | Strength |
---|---|
METHOTREXATE | 2.5 mg/mL |
SPL SET ID: | aec9984e-34c5-481b-b6bf-9bb5caf1daf8 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
52652-2001 | Xatmep | Xatmep |
0143-9367 | Methotrexate | Methotrexate |
0143-9516 | Methotrexate | Methotrexate |
0143-9517 | Methotrexate | Methotrexate |
0143-9518 | Methotrexate | Methotrexate |
0143-9519 | Methotrexate | Methotrexate |
0143-9830 | Methotrexate | Methotrexate |
0378-0014 | Methotrexate | methotrexate |
0555-0572 | Methotrexate | Methotrexate |
0703-3671 | Methotrexate | Methotrexate |
0703-3675 | Methotrexate | Methotrexate |
0703-3678 | Methotrexate | Methotrexate |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
XATMEP 86934766 5324671 Live/Registered |
Argentum Holdings, LLC 2016-03-09 |